ClinicalTrials.gg

TargetBeta

CSF1R

colony stimulating factor 1 receptor · also M-CSF-R, C-FMS, CSFR, CD115 · CD molecules

6 programs in company-led studies act on CSF1R, from 6 companies: 5 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
axatilimabruleIncytephase 3127 running–NCIt
pimicotinibruleAbbisko Caymanphase 3146 running–NCIt
quizartinibruleDaiichi Sankyophase 3225 runningFLT3, KIT, PDGFRA, PDGFRB, RETChEMBL
vimseltinibruleOno Pharmaceuticalphase 385 running–NCIt
seralutinibruleGB002, Inc., a wholly owned subsidiary of Gossamer Biophase 382 runningKIT, PDGFRA, PDGFRBChEMBL
adrixetinibruleQurientphase 232 runningAXLNCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.